According to TipRanks.com, Valiquette is a 2-star analyst with an average return of 0.3% and a 52.7% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Solventum ...

As of March 6 at 2:46:58 PM EST. Market Open.

In addition to Stifel Nicolaus, Zymeworks also received a Buy from LifeSci Capital’s Charles Zhu in a report issued yesterday. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on ...

XCells Biotechnologies USA, Inc. requests that their press release NewsItemId: 20260311932205 issued March 11, 2026 "iXCells Biotechnologies Reaches iPSC Line Delivery Milestone in Collaboration With ...

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is ...

2026年3月11日星期三,Zymeworks (NASDAQ:ZYME)在2026年Citizens生命科学大会上发表演讲,概述了其稳健的财务状况以及以创新和增长为核心的战略愿景。讨论重点介绍了其主打药物zanidatamab的巨大潜力,以及其雄心勃勃的扩张计划所涉及的战略风险。

Zymeworks Inc., a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, reported financial results ...

PSCore platform delivered over 500 characterized iPSC lines during first year of collaborationSAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human ...

The MarketWatch News Department was not involved in the creation of this content. -- Investment led by T&J Meyer Family Foundation, joined by Varia Ventures, NW Angel Fund and other non-institutional ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...